AstraZeneca Covid vaccine: Nearly a dozen countries resume AstraZeneca shots after EU, UK regulators say benefits outweigh risks | World news

AMSTERDAM / LONDON: Nearly a dozen countries resumed using Covid-19 shots at AstraZeneca on Friday as EU and British regulators said the benefits outweighed any risks following reports of rare blood samples which stopped from time to time.
The end of the allegations will begin a test of public confidence, both in the picture and in drug regulators whose decisions are under unprecedented scrutiny, the spread of virus changes and the global death toll, now at nearly 2.7 million, rising.
Indonesia has teamed up with Germany, France and others in reorganizing the scene after banning vaccines on reports of about 30 cases of rare brain blood clots, following millions of injections. -injection, which scientists and governments used to find out if there was a connection.
The European Medicines Agency (EMA) has clearly concluded that the benefits of the vaccine in protecting people from coronavirus-related death or hospital outweigh the potential risks. there.
However, the EMA said that a rare link between blood clots in the brain and the picture could not be definitively erased and would continue to be investigated, along with the British Medicines and Healthcare products Regulatory Agency (MHRA).
“This is a safe and effective vaccine,” EMA director Emer Cooke told a preparatory meeting Thursday. “If it was me, I’d be getting the vaccine tomorrow.”
The EMA said it will update its vaccination guidance to include patients with an explanation of the risks and potential information for health care professionals, to help people identify conditions when who may need to seek medical help after receiving the vaccine.
Following the EMA move, others are also being sought to reinforce confidence in the AstraZeneca vaccine, which is seen worldwide as an important asset due to its relatively easy storage and transportation requirements and cheap price. compared to mRNA vaccines made by Pfizer and Moderna.
“The thing we should be focusing on is that this is very encouraging. The processes are working, the safety audit that we are all expecting from our authorities is happening,” Andrew Pollard, who runs the Oxford Vaccination Group, told BBC radio, after both Regulators said vaccinations could continue following reports of blood clots.
“We have to keep a close eye on safety, but ultimately it’s the virus we’re fighting, not the vaccines. ”
Oxford University is in partnership with AstraZeneca on the vaccine.
Germany began administering the AstraZeneca vaccine from Friday morning, while French Prime Minister Jean Castex said he would try to encourage a similar resumption in his country by getting his own picture. Friday.
Italian Prime Minister Mario Draghi said Italy would follow suit, responding to comments from Cyprus, Latvia and Lithuania.
Spain will start onoculations from Wednesday. Canada also supported the vaccine.
The British MHRA is investigating five cases of the rare brain blood clot reported out of 11 million sightings reported in the UK.
They said he would investigate reports of clots in the cerebral veins (sinus vein thrombosis, or CSVT) occurring in combination with low-grade tumors shortly after vaccination. But the group said the use of the vaccine should continue and an official said the spread of Britain was unlikely to stop even if a link was confirmed.
The drug dealer’s own survey covering more than 17 million people who received the bullet in the EU and Britain found no evidence of an increased risk of blood clots.
The World Health Organization, which this week also confirmed support for the picture that remains a key part of its Covax vaccine distribution program, is expected Friday to provide an update on the review of vaccine advisory committee yourself.